Alivus Life Sciences share news, announcements and annual reports
NSE: ALIVUSBSE: 543322Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 29 Oct 2026. Previous close ₹1,399.40.
29 Oct: open ₹1,400.00, high ₹1,437.40, low ₹1,385.00
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹17,156 Cr502nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 28.45
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.15
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.36%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 22.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,64,40054.0% delivered
Alivus Life Sciences has 279 announcements on record, routine notices left out; 4 in the 30 days to 29 Oct 2026, the latest on 22 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Alivus Life Sciences quarterly results
The board meets on 29 Oct 2026 to consider financial results
Notice filed 21 Oct 2026
Alivus Life Sciences annual reports, presentations and earnings calls
The company's own documents, latest first.Alivus Life Sciences financials, year by year
Annual reports5
- Annual report, year to Mar 202611 Aug 2026
- Annual report, year to Mar 202512 Aug 2025
- Annual report, year to Mar 20242 Sep 2024
- Annual report, year to Mar 20231 Sep 2023, a zip file
- Annual report, year to Mar 202230 Aug 2022, a zip file
Investor presentations23
- Investor Presentation30 Jul 2026
- Investor Presentation14 May 2026
- Investor Presentation22 Jan 2026
- Investor Presentation6 Nov 2025
- Investor Presentation1 Aug 2025
18 earlier presentations
- Investor Presentation15 May 2025
- Investor Presentation23 Jan 2025
- Investor Presentation24 Oct 2024
- Investor Presentation25 Jul 2024
- Investor Presentation25 Apr 2024
- Investor Presentation11 Mar 2024
- Investor Presentation23 Jan 2024
- Investor Presentation20 Oct 2023
- Investor Presentation21 Jul 2023
- Investor Presentation27 Apr 2023
- Investor Presentation27 Jan 2023
- Investor Presentation17 Nov 2022
- Further to our communication dated November 11, 2022, attached is a copy of the presentation to be made at Glenmark Life Sciences Limited - Investor Day 2022 which is scheduled today at 15:45 IST in Mumbai.Kindly take the same on record and acknowledge receipt.17 Nov 2022
- Investor Presentation21 Oct 2022
- We are enclosing the investor presentation.4 Aug 2022
- We are enclosing the investor presentation.20 Apr 2022
- Investor Presentation8 Feb 2022
- Investor Presentation10 Nov 2021
Earnings calls32
- Transcript of earnings call held on July 31, 2026.7 Aug 2026
- Link of Recording31 Jul 2026
- Transcript of Earnings Call.21 May 2026
- Link of Earnings Call Recording15 May 2026
- Transcript of Earnings Call30 Jan 2026
27 earlier call documents
- Link of Recording of Earnings Call22 Jan 2026
- Transcript13 Nov 2025
- Weblink of Recording of Earnings Call Q2 FY2026.7 Nov 2025
- Transcript8 Aug 2025
- Link of Recording2 Aug 2025
- Transcript23 May 2025
- Link of Recording16 May 2025
- Transcript30 Jan 2025
- Link of Recording23 Jan 2025
- Transcript31 Oct 2024
- Link of Recording25 Oct 2024
- Transcript2 Aug 2024
- Link of Recording26 Jul 2024
- Transcript3 May 2024
- Link of Recording26 Apr 2024
- Transcript31 Jan 2024
- Link of Recording24 Jan 2024
- Transcript25 Oct 2023
- Transcript24 Jul 2023
- Link of Recording21 Jul 2023
- Transcript2 May 2023
- Link of Recording28 Apr 2023
- Transcript1 Feb 2023
- Link of Recording28 Jan 2023
- Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, October 21, 2022 for the quarter and half year ended September 30, 2022 is available on the Company's website at:https://www.glenmarklifesciences.com/pdf/Transcript%20of%20Earnings%20Concall%20Q2%20FY2022-23.pdfThe said transcript is also attached.27 Oct 2022
- Pursuant to Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, the transcript of the Earnings call held on Friday, 5th August, 2022 for the quarter ended June 30, 2022 is available on the Company's website at:https://www.glenmarklifesciences.com/pdf/Transcript%20of%20Earnings%20Concall%20Q1%20FY2022-23.pdf8 Aug 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call5 Aug 2022
Alivus Life Sciences share news and announcements
Newest first. Page 1 of 6.
Oct 2026
22 Oct · Analysts
9 Oct
7 Oct · General Updates
Sep 2026
16 Sep · General Updates
11 Sep · Analysts
7 Sep · Analysts
5 Sep · Analysts
Aug 2026
25 Aug · Analysts
13 Aug · Analysts
11 Aug · Updates
7 Aug · Analysts
7 Aug · Analysts
Jul 2026
30 Jul · Results
23 Jul · Analysts
23 Jul · Board meeting
Jun 2026
23 Jun · Analysts
10 Jun · Analysts
4 Jun · Analysts
May 2026
20 May · Analysts
19 May · Analysts
14 May · Disclosure
14 May · Results
8 May · Analysts
Mar 2026
21 Mar
12 Mar · Analysts
6 Mar · Analysts
Feb 2026
25 Feb · Updates
16 Feb
2 Feb · Analysts
Jan 2026
30 Jan
28 Jan · Analysts
22 Jan · Results
21 Jan · Disclosure
15 Jan · Analysts
Dec 2025
24 Dec · Analysts
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 31 Jul 2026Resultsup 5.87%+5.4 pts vs Nifty 500market median −0.7% · five sessions +20.9% (+19.3 pts vs Nifty 500) · volume 2.8× usual · delivery −26.1 pts against usual · The announcement
- 15 May 2026Resultsdown 1.83%−1.5 pts vs Nifty 500market median −0.7% · five sessions −0.7% (−0.7 pts vs Nifty 500) · volume 1.8× usual · delivery +7.1 pts against usual · The announcement
- 7 Nov 2025Resultsup 2.76%+2.7 pts vs Nifty 500market median −0.7% · five sessions +1.5% (+0.2 pts vs Nifty 500) · volume 1.6× usual · delivery −11.8 pts against usual · The announcement
- 17 Sep 2025Credit ratingup 0.26%−0.1 pts vs Nifty 500market median 0.0% · five sessions +5.0% (+5.2 pts vs Nifty 500) · volume 1.5× usual · delivery +17.2 pts against usual · The announcement
- 4 Aug 2025Resultsdown 3.49%−4.3 pts vs Nifty 500market median −0.7% · five sessions −6.6% (−5.6 pts vs Nifty 500) · volume 1.6× usual · delivery −7.7 pts against usual · The announcement
- 16 May 2025Resultsdown 5.26%−5.6 pts vs Nifty 500market median −0.7% · five sessions −8.5% (−7.6 pts vs Nifty 500) · volume 2.1× usual · delivery −10.3 pts against usual · The announcement
- 16 May 2025Dividenddown 5.26%−5.6 pts vs Nifty 500market median 0.0% · five sessions −8.5% (−7.6 pts vs Nifty 500) · volume 2.1× usual · delivery −10.3 pts against usual · The announcement
- 20 Jun 2024Credit ratingdown 0.70%−1.1 pts vs Nifty 500market median 0.0% · five sessions −0.4% (−1.3 pts vs Nifty 500) · volume 0.3× usual · The announcement
- 24 Apr 2024Board or managers changedup 0.03%−0.3 pts vs Nifty 500market median 0.0% · five sessions +0.3% (−1.3 pts vs Nifty 500) · volume 0.3× usual · The announcement
- 22 Apr 2024Board or managers changedup 4.60%+3.7 pts vs Nifty 500market median 0.0% · five sessions +1.5% (−0.7 pts vs Nifty 500) · volume 1.4× usual · The announcement
8 earlier announcements
- 7 Mar 2024Board or managers changedup 3.95%+3.7 pts vs Nifty 500market median 0.0% · five sessions −1.9% (+0.4 pts vs Nifty 500) · volume 1.3× usual · The announcement
- 10 Oct 2023Dividendup 1.57%+0.5 pts vs Nifty 500market median 0.0% · five sessions +7.1% (+5.6 pts vs Nifty 500) · volume 1.2× usual · The announcement
- 5 Oct 2023Credit ratingup 0.12%−0.3 pts vs Nifty 500market median 0.0% · five sessions +2.8% (+1.1 pts vs Nifty 500) · volume 2.8× usual · The announcement
- 25 Sep 2023Credit ratingdown 2.33%−2.4 pts vs Nifty 500market median 0.0% · five sessions −4.2% (−4.4 pts vs Nifty 500) · volume 1.7× usual · The announcement
- 17 Mar 2023Dividendup 5.04%+4.4 pts vs Nifty 500market median 0.0% · five sessions +6.8% (+6.3 pts vs Nifty 500) · volume 3.2× usual · The announcement
- 21 Oct 2022Board or managers changeddown 0.22%0.0 pts vs Nifty 500market median 0.0% · five sessions +2.4% (+1.5 pts vs Nifty 500) · volume 0.2× usual · The announcement
- 21 Apr 2022Board or managers changeddown 0.13%−1.5 pts vs Nifty 500market median 0.0% · five sessions −0.9% (−0.3 pts vs Nifty 500) · volume 1.0× usual · The announcement
- 8 Nov 2021Dividendup 0.62%−0.3 pts vs Nifty 500market median 0.0% · five sessions +2.4% (+1.1 pts vs Nifty 500) · volume 0.7× usual · The announcement
Alivus Life Sciences results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.